Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis

BACKGROUND: Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system. OBJECTIVE: To conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinum...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Helen Y., Keller, Elena, Suresh, Harish, Sebaratnam, Deshan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593743/
https://www.ncbi.nlm.nih.gov/pubmed/34816130
http://dx.doi.org/10.1016/j.jdin.2021.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593743/
https://www.ncbi.nlm.nih.gov/pubmed/34816130
http://dx.doi.org/10.1016/j.jdin.2021.06.004

Ejemplares similares